Igor Matushansky M.D., Ph.D.
Net Worth
Last updated:
What is Igor Matushansky M.D., Ph.D. net worth?
The estimated net worth of Dr. Igor Matushansky M.D., Ph.D. is at least $4,480,189 as of 21 Dec 2021. He owns shares worth $65,385 as insider, has earned $797,224 from insider trading and has received compensation worth at least $3,617,580 in HOOKIPA Pharma Inc..
What is the salary of Igor Matushansky M.D., Ph.D.?
Dr. Igor Matushansky M.D., Ph.D. salary is $602,930 per year as Chief Medical Officer and Global Head of R&D in HOOKIPA Pharma Inc..
How old is Igor Matushansky M.D., Ph.D.?
Dr. Igor Matushansky M.D., Ph.D. is 52 years old, born in 1973.
What stocks does Igor Matushansky M.D., Ph.D. currently own?
As insider, Dr. Igor Matushansky M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| HOOKIPA Pharma Inc. (HOOK) | Chief Medical Officer and Global Head of R&D | 80,178 | $0.82 | $65,385 |
What does HOOKIPA Pharma Inc. do?
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Igor Matushansky M.D., Ph.D. insider trading
HOOKIPA Pharma Inc.
Dr. Igor Matushansky M.D., Ph.D. has made 7 insider trades between 2019-2021, according to the Form 4 filled with the SEC. Most recently he sold 14,949 units of HOOK stock worth $37,223 on 21 Dec 2021.
The largest trade he's ever made was exercising 48,988 units of HOOK stock on 17 Dec 2020. As of 21 Dec 2021 he still owns at least 80,178 units of HOOK stock.
HOOKIPA Pharma key executives
HOOKIPA Pharma Inc. executives and other stock owners filed with the SEC:
- Dr. Igor Matushansky M.D., Ph.D. (52) Chief Medical Officer and Global Head of R&D
- Dr. Reinhard Kandera (56) Chief Financial Officer & Director
- Mr. Joern Aldag (66) Chief Executive Officer & Director